Suppr超能文献

住院患者植入无导线起搏器后的死亡率和 30 天再入院率:来自全国再入院数据库的见解。

Mortality and 30-Day Readmission Rates After Inpatient Leadless Pacemaker Implantation: Insights From a Nationwide Readmissions Database.

机构信息

Department of Medical and Health Information Management, National Cerebral and Cardiovascular Centre, Suita, Japan.

Department of Medical and Health Information Management, National Cerebral and Cardiovascular Centre, Suita, Japan.

出版信息

Can J Cardiol. 2022 Nov;38(11):1697-1705. doi: 10.1016/j.cjca.2022.08.002. Epub 2022 Aug 11.

Abstract

BACKGROUND

This study aimed to provide real-world data on the rates, trends, and predictors of in-hospital complications and 30-day readmission following leadless pacemaker (LP) implantation.

METHODS

We analysed leadless and conventional pacemaker implantations with the use of the all-payer, nationally representative Nationwide Readmissions Database from 2017 to 2019. The national trends of in-hospital mortality, in-hospital complications, and 30-day readmission rates after pacemaker implantation were analysed. Mixed-effects multivariable logistic regression analysis was performed to identify factors associated with in-hospital death and 30-day readmission in LP patients.

RESULTS

A total of 137,732 admissions (age 78 years, IQR 70-85 years, 5986 LP implantations) were analysed. The in-hospital mortality, overall in-hospital complication, and 30-day readmission rates after LP implantations were 5.0%, 16%, and 16%, respectively. In LP recipients, the national estimate of in-hospital mortality declined from 10.9% in the second quarter of 2017 to 4.3% in the fourth quarter of 2019 (P < 0.001). Furthermore, the national estimate of overall complications declined from 20.6% in the second quarter of 2017 to 13.0% in the fourth quarter of 2019 (P < 0.001). In LP recipients, female sex, history of chronic kidney disease, heart failure, and malnutrition were factors associated with in-hospital death.

CONCLUSIONS

Analysis of the nationally representative claims database from the United States showed in-hospital mortality and complication rates (for LP implantation performed during hospitalisation) of 5.0% and 16%, respectively. Although these rates showed a decreasing trend over time, ongoing surveillance is needed for the safety of LP implantation.

摘要

背景

本研究旨在提供关于无导线起搏器(LP)植入后住院期间并发症和 30 天再入院率的真实世界数据、趋势和预测因素。

方法

我们使用 2017 年至 2019 年全美再入院数据库(一个覆盖所有支付方的全国代表性数据库)分析了无导线和传统起搏器植入。分析了起搏器植入后住院期间死亡率、住院期间并发症和 30 天再入院率的全国趋势。采用混合效应多变量逻辑回归分析确定与 LP 患者住院期间死亡和 30 天再入院相关的因素。

结果

共分析了 137732 例入院(年龄 78 岁,IQR 70-85 岁,5986 例 LP 植入)。LP 植入后住院期间死亡率、总体住院期间并发症和 30 天再入院率分别为 5.0%、16%和 16%。在 LP 接受者中,全国范围内 LP 植入后住院期间死亡率从 2017 年第二季度的 10.9%下降到 2019 年第四季度的 4.3%(P<0.001)。此外,全国范围内总体并发症发生率从 2017 年第二季度的 20.6%下降到 2019 年第四季度的 13.0%(P<0.001)。在 LP 接受者中,女性、慢性肾脏病史、心力衰竭和营养不良是与住院期间死亡相关的因素。

结论

对来自美国的具有全国代表性的索赔数据库进行分析显示,LP 植入术后住院期间死亡率和并发症发生率分别为 5.0%和 16%。尽管这些比率随时间呈下降趋势,但仍需对 LP 植入的安全性进行持续监测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验